Show simple item record

Authordc.contributor.authorWoudt, Lisanne 
Authordc.contributor.authorDi Capua, Gabriella A. 
Authordc.contributor.authorKrahn, Martin 
Authordc.contributor.authorCastiglioni, Claudia 
Authordc.contributor.authorHughes García, Ricardo 
Authordc.contributor.authorCampero Soffia, Mario 
Authordc.contributor.authorTrangulao, Alejandra 
Authordc.contributor.authorGonzález Hormazabal, Patricio 
Authordc.contributor.authorGodoy Herrera, Raúl 
Authordc.contributor.authorLevy, Nicolas 
Authordc.contributor.authorUrtizberea, Jon Andoni 
Authordc.contributor.authorJara, Lilian 
Authordc.contributor.authorBevilacqua, Jorge 
Admission datedc.date.accessioned2016-06-28T20:35:17Z
Available datedc.date.available2016-06-28T20:35:17Z
Publication datedc.date.issued2016
Cita de ítemdc.identifier.citationMuscle Nerve 53: 49–57, 2016en_US
Identifierdc.identifier.otherDOI: 10.1002/mus.24685
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/139174
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractIntroduction: Understanding the natural history of dysferlinopathy is essential to design and quantify novel therapeutic protocols. Our aim in this study was to assess, clinically and functionally, a cohort of patients with dysferlinopathy, using validated scales. Methods: Thirty-one patients with genetically confirmed dysferlinopathy were assessed using the motor function measure (MFM), Modified Rankin Scale (MRS), Muscle Research Council (MRC) scale, serum creatine kinase (CK) assessment, baseline spirometry data, and echocardiographic and electrophysiologic studies. Results: MFM and MRC scores showed a significant negative correlation with disease duration and inverse correlation with MRS, but not with onset age, clinical phenotype, or CK levels. Percent forced vital capacity (% FVC) correlated negatively with disease duration and onset age. Eight known pathogenic mutations were identified recurrently, 4 of which accounted for 79% of the total. Conclusions: The results suggest that MFM is a reliable outcome measure that may be useful for longitudinal follow-up in dysferlinopathy. Recurrent mutations suggest a founder effect in the Chilean population.en_US
Lenguagedc.language.isoenen_US
Publisherdc.publisherWILEY-BLACKWELLen_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectRecurrent mutationsen_US
Keywordsdc.subjectMRC scoreen_US
Keywordsdc.subjectMotor function measureen_US
Keywordsdc.subjectDYSFen_US
Keywordsdc.subjectDysferlinopathyen_US
Títulodc.titleToward an objective measure of functional disability in dysferlinopathyen_US
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile